Edwards Lifesciences (EW) reported a strong financial performance for 2025, achieving an 11% increase in total revenue. Looking ahead to 2026, the medical device maker expects sales growth to remain steady between 8% and 10%. The company also issued positive guidance for adjusted earnings per share (EPS), forecasting a range of $2.90 to $3.05. A significant driver of this growth is the TMTT segment, which is projected to see a 40% surge in sales. This momentum is further supported by the company's robust cash position and ongoing share buyback programs. Overall, the continued strength in core heart valve therapies positions the firm for sustained market leadership.
Sign up free to access this content
Create Free Account